

Special Issue

Targeted Immunotherapy in Cancer

Message from the Guest Editor

Cancer immunotherapy is a revolutionary approach in the field of cancer treatment that harnesses the power of the immune system to fight cancer cells. It represents a significant paradigm shift from traditional cancer treatments such as surgery, chemotherapy, and radiation therapy. While cancer immunotherapy has shown remarkable success in treating certain types of cancer, it is important to acknowledge the challenges and limitations that present specifically and effectively, particularly in targeting cancer cells. This Special Issue aims to provide a comprehensive overview of the latest advancements and emerging trends in targeted cancer immunotherapy. We welcome original research articles, reviews, and perspective articles on this theme. Topics may include, but are not limited to:

- Novel technology to deliver immunotherapeutics to target locations.
- On-off switch for CAR-T cell therapy.
- Providing cancer-targeting moiety to immunotherapeutics.
- Immunotherapy-related toxicities and management.
- Translational research in cancer immunotherapy using an advanced animal model.

Guest Editor

Dr. Masakazu Kamata

Department of Microbiology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35294, USA

Deadline for manuscript submissions

closed (20 May 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/175935

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).